par Zilli, Thomas;Dirix, Piet;Heikkilä, Reino;Liefhooghe, Nick;Siva, Shankar;Gómez-Iturriaga, Alfonso;Everaerts, Wouter;Otte, François-Xavier 
;Shelan, Mohamed;Mercier, Carole;Achard, Vérane;Thon, Kristian;Stellamans, Karin;Moon, Daniel;Conde-Moreno, Antonio José A.;Papachristofilou, Alexandros;Scorsetti, Marta;Gückenberger, Matthias;Ameye, Filip;Zapatero, Almudena;Van De Voorde, Lien;López-Campos, Fernando;Couñago, F.;Jaccard, Maud;Spiessens, A.;Semac, I.;Vanhoutte, Frederik;Goetghebeur, Els;Reynders, Dries;Ost, P.
Référence European Urology Focus, 7, 2, page (241-244)
Publication Publié, 2021-03
;Shelan, Mohamed;Mercier, Carole;Achard, Vérane;Thon, Kristian;Stellamans, Karin;Moon, Daniel;Conde-Moreno, Antonio José A.;Papachristofilou, Alexandros;Scorsetti, Marta;Gückenberger, Matthias;Ameye, Filip;Zapatero, Almudena;Van De Voorde, Lien;López-Campos, Fernando;Couñago, F.;Jaccard, Maud;Spiessens, A.;Semac, I.;Vanhoutte, Frederik;Goetghebeur, Els;Reynders, Dries;Ost, P.Référence European Urology Focus, 7, 2, page (241-244)
Publication Publié, 2021-03
Article révisé par les pairs
| Résumé : | Optimal local treatment for nodal oligorecurrent prostate cancer is unknown. The randomized phase 2 PEACE V-STORM trial will explore the best treatment approach in this setting. Early results on the acute toxicity profile are projected to be published in quarter 3, 2021. |
